GenMont Biotech Incorporation Stock

Equities

3164

TW0003164000

Food Processing

End-of-day quote Taiwan S.E. 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
22.25 TWD +0.23% Intraday chart for GenMont Biotech Incorporation -1.98% -9.92%
Sales 2022 369M 11.33M Sales 2023 318M 9.78M Capitalization 2.14B 65.69M
Net income 2022 57M 1.75M Net income 2023 33M 1.01M EV / Sales 2022 4.56 x
Net cash position 2022 366M 11.26M Net cash position 2023 270M 8.3M EV / Sales 2023 5.87 x
P/E ratio 2022
35.9 x
P/E ratio 2023
65 x
Employees -
Yield 2022
2.95%
Yield 2023
-
Free-Float 62.07%
More Fundamentals * Assessed data
Dynamic Chart
GenMont Biotech Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GenMont Biotech Incorporation Proposes Cash Dividend for the Year Ended December 31, 2023 CI
GenMont Biotech Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GenMont Biotech Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GenMont Biotech Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GenMont Biotech Incorporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GenMont Biotech Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
GenMont Biotech Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
GenMont Biotech Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GenMont Biotech Incorporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
GenMont Biotech Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Genmont Biotech Incorporation Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Genmont Biotech Incorporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Genmont Biotech Incorporation Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Genmont Biotech Incorporation Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
1 day+0.23%
1 week-1.98%
Current month-0.45%
1 month+0.23%
3 months-5.92%
6 months-2.63%
Current year-9.92%
More quotes
1 week
21.90
Extreme 21.9
22.55
1 month
21.40
Extreme 21.4
22.95
Current year
21.40
Extreme 21.4
24.80
1 year
21.40
Extreme 21.4
27.50
3 years
21.00
Extreme 21
31.05
5 years
16.20
Extreme 16.2
31.05
10 years
16.20
Extreme 16.2
52.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 08-04-29
Director of Finance/CFO - 05-01-09
Chief Operating Officer - 14-03-09
Members of the board TitleAgeSince
Chairman - 05-06-29
Director/Board Member - 06-06-29
Director/Board Member - 14-04-29
More insiders
Date Price Change Volume
24-04-18 22.25 +0.23% 25,562
24-04-17 22.2 +0.91% 22,903
24-04-16 22 -2.44% 110,209
24-04-15 22.55 -0.88% 115,835
24-04-12 22.75 +0.22% 139,834

End-of-day quote Taiwan S.E., April 17, 2024

More quotes
GenMont Biotech Incorporation is a Taiwan-based company principally engaged in the manufacture and distribution of functional lactobacillus. The Company's major products include lactobacillus paracasei, lactobacillus rhamnosus, lactobacillus casei, lactobacillus plantarum, lactobacillus fermentum, lactobacillus salivarius, lactobacillus acidophilus, lactobacillus reuteri, lactobacillus brevis, lactobacillus bulgaricus, lactobacillus gasseri, lactobacillus johnsonii and others. The Company’s products are applied to enhance human immunity against dust allergy and digestive system health care. The Company distributes its products in domestic market and to overseas markets.
More about the company